Pharmacogenomic Contributions to Trihexyphenidyl Biotransformation and Response in Children With Dystonic Cerebral Palsy
Key facts
- Where
- Kansas City, United StatesSee the site
- Phase
- Phase 1
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 5 and 17 years old?
Source: NCT06554288, who can take part
Where in United States
- Children's Mercy Hospital, Kansas CityKansas City, United StatesContact: Rachel NassTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Children's Mercy Hospital Kansas City
- Trial code
- NCT06554288
- Record updated
- 24 June 2026
- Original description
This study looks at how a medicine called trihexyphenidyl works in children with dystonic cerebral palsy. The study aims to understand how trihexyphenidyl is broken down and used in the body of pediatric patients and whether this is impacted by a person's genetics. Information from this study will also be used to design future clinical trials.Read full original descriptionShow less
Pharmacogenomic Contribution to the Biotransformation of Trihexyphenidyl and Development of a Precision Dosing Model for Children With Dystonia and Cerebral Palsy
This study looks at how a medicine called trihexyphenidyl works in children with dystonic cerebral palsy. The study aims to understand how trihexyphenidyl is broken down and used in the body of pediatric patients and whether this is impacted by a person's genetics. Information from this study will also be used to design future clinical trials.
Inclusion: Ages 5-17 years of age; Diagnosis of cerebral palsy and dystonia causing interference; Parent/legal guardian of a child with a diagnosis of cerebral palsy and dystonia; Parent/legal guardian is willing and able to provide informed permission/assent for the study.
Exclusion: Previously or currently taking trihexyphenidyl; Patients turning 18 years of age within the study period (16 weeks from Study Day 1); A language barrier for the patient that precludes communication and/or the ability to complete study-related requirements.